ResearcherVall d'Hebron Hospital UniversitariNo recent work listed
Kim Pedersen
Matched on OpenAlex author ID A5063031385. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper
Papers 3
- The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. Co-author DOI 10.1158/0008-5472.can-20-4263↗
- Pancreatic cancer heterogeneity and response to Mek inhibition. Co-author DOI 10.1038/onc.2017.174↗
- Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-14-2852↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Joaquı́n Arribas · 3 shared papers, 2015–2021 · strength 0.23
- Paper The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. DOI 10.1158/0008-5472.can-20-4263↗
- Paper Pancreatic cancer heterogeneity and response to Mek inhibition. DOI 10.1038/onc.2017.174↗
- Paper Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. DOI 10.1158/0008-5472.can-14-2852↗
- Faiz Bilal · 2 shared papers, 2017–2021 · strength 0.18
- Josep M. Tabernero · 2 shared papers, 2017–2021 · strength 0.18
- Teresa Mercade Macarulla · 2 shared papers, 2017–2021 · strength 0.18
- Silvestre Vicent · 1 shared paper, 2021 · strength 0.13
- Daniel Massó-Vallés · 2 shared papers, 2015–2017 · strength 0.10
- Laura Soucek · 2 shared papers, 2015–2017 · strength 0.10
- Irit Sagi · 1 shared paper, 2017 · strength 0.06
- Vishnu Mohan · 1 shared paper, 2017 · strength 0.06
- Ana P. Vivancos · 1 shared paper, 2017 · strength 0.06
- Nicole M. Sodir · 1 shared paper, 2015 · strength 0.05
- Toni Jauset · 1 shared paper, 2015 · strength 0.05
- Gérard I. Evan · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.